NCT02265562

Brief Summary

Hysterectomy, as any major operation, can cause complications, as hemorrhage which may occur in some cases and sometimes requiring blood transfusion. Recent study proved that misoprostol success in reducing blood loss during total abdominal hysterectomy when used once before the surgery.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
220

participants targeted

Target at P25-P50 for phase_3

Timeline
Completed

Started Oct 2014

Shorter than P25 for phase_3

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2014

Completed
9 days until next milestone

First Submitted

Initial submission to the registry

October 10, 2014

Completed
6 days until next milestone

First Posted

Study publicly available on registry

October 16, 2014

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2015

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2015

Completed
Last Updated

October 16, 2014

Status Verified

October 1, 2014

Enrollment Period

7 months

First QC Date

October 10, 2014

Last Update Submit

October 15, 2014

Conditions

Keywords

HysterectomyMisoprostolBlood loss

Outcome Measures

Primary Outcomes (1)

  • Blood loss

    amount of intra-operative blood loss

    8 months

Secondary Outcomes (1)

  • postoperative hemoglobin level

    8 months

Study Arms (2)

Misoprostol

EXPERIMENTAL

60 minutes before the surgery 400 μg of misoprostol (2 tablets of 200 μg) inserted rectally

Drug: Misoprostol

Placebo

PLACEBO COMPARATOR

60 minutes before the surgery 2 tablets of placebo tablets inserted rectally

Drug: Placebo

Interventions

60 minutes before the surgery 400 μg of misoprostol (2 tablets of 200 μg) inserted rectally

Also known as: prostaglandin E1 analogue
Misoprostol

60 minutes before the surgery 2 tablet of placebo inserted rectally

Also known as: Dizirest B6
Placebo

Eligibility Criteria

Age18 Years - 80 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • A- Age: adult female \>18 years old. B- Any women undergoing abdominal hysterectomy. C- No contraindications to misoprostol.

You may not qualify if:

  • A -Women with any contraindications to misoprostol including heart disease, mitral stenosis , severe hypertension ( diastolic pressure over100mm Hg) , hematologic disorders (as sickle cell anemia ), glaucoma, bronchial asthma, liver disease.
  • B- Known history of or active medical disorder as DM . C- Pelvic endometriosis and adnexal mass. D- Those who had undergone previous myomectomy. E- Women who received GnRH analogues and mifepristone and who are allergic to prostaglandins.
  • F- Women with mental impairment or incompetent in giving consent. G- Women who don't wish to participate in the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Cairo University hospiatl

Cairo, 12311, Egypt

RECRUITING

MeSH Terms

Conditions

Hemorrhage

Interventions

Misoprostol

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Prostaglandins E, SyntheticProstaglandins, SyntheticProstaglandinsEicosanoidsFatty Acids, UnsaturatedFatty AcidsLipidsAutacoidsInflammation MediatorsBiological Factors

Study Officials

  • Waleed El-khyatat, M.D.

    Cairo University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Waleed EL-khayat, M.D.

CONTACT

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor of Obstetrics & Gynecology

Study Record Dates

First Submitted

October 10, 2014

First Posted

October 16, 2014

Study Start

October 1, 2014

Primary Completion

May 1, 2015

Study Completion

June 1, 2015

Last Updated

October 16, 2014

Record last verified: 2014-10

Locations